Palivizumab Biosimilar - Anti-RSV mAb - Research Grade
Source
CAS 188039-54-5
Species
Humanized
Expression system
Mammalian cells
Purity
>85%
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Palivizumab,MEDI-493, Synagis,RSV,anti-RSV
Reference
PX-TA1057
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG1-kappa
Clonality
Monoclonal Antibody
Description of Palivizumab Biosimilar - Anti-RSV mAb - Research Grade
General information on Anti-RSV(Respiratory syncytial virus) (Palivizumab) Monoclonal Antibody
Palivizumab is a humanized monoclonal antibody of isotype IgG1k produced by recombinant DNA technology. It targets the epitope in the A antigenic site of the respiratory syncytial virus (RSV) F protein.
SDS-PAGE for Palivizumab Biosimilar - Anti-RSV mAb
Palivizumab Biosimilar - Anti-RSV mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Palivizumab Biosimilar - Anti-RSV mAb binds to HRSV-A2 Pre-F-Fusion glycoprotein F0 recombinant protein in indirect ELISA Assay
Immobilized HRSV-A2 Pre-F-Fusion glycoprotein F0 recombinant protein (cat. No.PX-P6126) at 0.5µg/mL (100µL/well) can bind to Palivizumab Biosimilar - Anti-RSV mAb (cat. No.PX-TA1057) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Palivizumab Biosimilar – Anti-RSV mAb – Research Grade” Cancel reply
Reviews
There are no reviews yet.